ESC Premium Access

Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

Congress Session

About the speaker

Doctor Thomas A Zelniker

General Hospital Vienna, Medical University of Vienna, Vienna (Austria)
0 follower

4 more presentations in this session

State of the Art - SGLT2 inhibitors in cardiovascular disease

Speaker: Professor M. Sabatine (Boston, US)

Thumbnail

Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

Speaker: Doctor J. Udell (Toronto, CA)

Thumbnail

SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes

Speaker: Doctor C. Noergaard (Aalborg, DK)

Thumbnail

Integrating SGLT2 inhibitors in diabetes treatment: a guide for cardiologists

Speaker: Professor N. Sattar (Glasgow, GB)

Thumbnail

Access the full session

New frontiers: SGLT2 inhibitors in cardiorenal disease

Speakers: Doctor T. Zelniker, Professor M. Sabatine, Doctor J. Udell, Doctor C. Noergaard, Professor N. Sattar
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

Related content

Open Access

HF patient at the center of his monitoring.

29 June 2021

Open Access

New perspectives of digital medicine in HF.

29 June 2021

Open Access

Introduction: How ehealth will change patient pathway.

29 June 2021

This platform is supported by

logo Novo Nordisk